76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Agios Pharmaceuticals Inc
Open
SectorHealthcare
28.75 2.57
Overview
Share price change
24h
Min
27.86
Max
28.81
Income | 7.2M -89M |
|---|---|
Sales | -2M 8.7M |
P/E Sector Avg | 2.525 56.602 |
EPS | -1.55 |
Profit margin | -1,023.252 |
Employees | 486 |
EBITDA | 17M -107M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +96.99% upside |
Next Earnings | 31 Jul 2025 |
|---|
Market Cap | -211M 1.7B |
|---|---|
Previous open | 26.18 |
Previous close | 28.75 |
News Sentiment
By Acuity
50%
50%
173 / 382 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Agios Pharmaceuticals Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Agios Pharmaceuticals Inc Forecast
Price Target
By TipRanks
96.99% upside
12 Months Forecast
Average 55.67 USD 96.99%
High 71 USD
Low 43 USD
Based on 8 Wall Street analysts offering 12 month price targets forAgios Pharmaceuticals Inc - Dist in the last 3 months.
Sentiment
By Acuity
173 / 382 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Agios Pharmaceuticals Inc
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
